Hemophilia
We recommend
Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment
With the development of new treatment options for hemophilia, there has also been progress in methods for monitoring hemophilic arthropathy and identifying it in its early stages. In addition to classical X-rays, clinical scoring systems, and the gold standard of magnetic resonance imaging (MRI), the so-called POCUS – point-of-care ultrasound – has emerged as a quick and reliable method for assessing joint health. Potential biomarkers for osteochondral damage and synovial proliferation specific to hemophilia or for detecting joint…
Collagen Turnover as a Biomarker of Hemophilia Treatment Efficacy
Over the past decades, hemophilia treatment has made significant progress—from factor therapy to…
FEIBA in Real Clinical Practice – Fresh Data from the Observational Study FEIBA GO
FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term…
Articles on this topic
Untreated Bleeding in Hemophilia A – An Underestimated Problem? To What Extent?
How common is bleeding in hemophilia A that ultimately goes untreated? This was the focus of a…
Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year − A US Experience
The authors of a recent study, summarizing real-world experience from the US, focused on the…
Safety of aPCC in Real Practice – Results of the BAHAS Project
What are the experiences with activated prothrombin complex concentrate (aPCC) in controlling…
Current Expert Consensus on Prophylaxis of Individuals with Mild and Moderate Hemophilia A: These Patients Also Deserve Better Care
What is the importance of prophylaxis in 'non-severe' hemophilia A? Italian doctors have…
Non-factor vs. Factor Prophylaxis of Hemophilia A: A Comparison of Cost and Treatment Effectiveness Based on Real-World Data from the USA
In the prophylactic treatment of patients with hemophilia A, particularly its severe form,…
Model of Risk of Bleeding Associated with Physical Activity in Hemophiliacs with Factor and Non-Factor Treatment
In the treatment of hemophilia A, both FVIII concentrate replacement therapy and non-factor…
Dosing and Consumption of rFVIII Products with Extended Half-life in Patients with Hemophilia A in Real-World Practice
Based on real-world data from the USA, a recently published study compared two recombinant…
Efficacy and Safety of Two Pharmacokinetically-Driven Prophylactic Regimens in People with Hemophilia A
Standard prophylaxis for bleeding in hemophilia A, based on the administration of coagulation…
Critical Overview of Clinical Studies on EHL FVIII Preparations
An international team of experts recently published a comprehensive work evaluating the…
Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation…
1
2
Subscribe
E-courses on this topic
Most read on this topic
- Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
- Current Expert Consensus on Prophylaxis of Individuals with Mild and Moderate Hemophilia A: These Patients Also Deserve Better Care
- Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A
- Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
- Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
- Dosing and Consumption of rFVIII Products with Extended Half-life in Patients with Hemophilia A in Real-World Practice
Journal on this topic
Related topic
Interesting links